CEO Jeremy Bender (Day One)
It’s a new $DAWN for Day One as startup pivots to an IPO for more funding to back its work in pediatric cancer
Pediatric cancer biotech Day One Pharmaceuticals is headed for Nasdaq, in a move that comes less than three months after their work on a brain …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
